Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Sanofi-aventis reports encouraging diabetes drug trial data

Sanofi-aventis reports encouraging diabetes drug trial data

12th April 2011

Sanofi-aventis has expressed satisfaction with the performance of its developmental type 2 diabetes drug lixisenatide in a phase III clinical study.

The new GLP-1 receptor has met its primary efficacy endpoint in the GetGoal-S trial, demonstrating significant reductions in levels of glycated haemoglobin and improved glycaemic control when compared to placebo.

This was achieved without an accompanying increase in the risk of hypoglycaemia, while the drug was also shown to help patients to achieve a reduction in body weight.

GetGoal-S is one of a total of nine studies being conducted as part of the GetGoal phase III clinical programme, which commenced in May 2008 and has enrolled more than 4,300 patients to date.

Pierre Chancel, senior vice-president for the global diabetes division at Sanofi-aventis, said: "The results of GetGoal-S are another positive step for lixisenatide and reinforce the efficacy and safety profile of this new GLP-1."

Earlier this week, the company announced the formal completion of its takeover of Genzyme, a move that will significantly expand its global presence.ADNFCR-8000103-ID-800496073-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.